Antigen tests sa COVID-19 planong gamitin ng pamahalaan

By Chona Yu July 23, 2020 - 12:14 PM

Pinag-aaralan na ng Inter Agency Task Force for the Management of Emerging Infectious Diseases ang paggamit ng bagong teknolohiya para sa pagtukoy ng COVID-19 kung saan makukuha ang resulta sa loob lamang ng 30-minuto.

Ayon kay Cabinet Secretary at IATF co-chairman Karlo Alexi Nograles, ito ay ang antigen tests.

“Of course alam natin meron gumagamit ng rapid test kits. But there’s also a new technology, which is also lab-based, but will have a faster turnaround which is the antigen test. The antigen test is another technology that we recently discussed in the IATF and we’ve sent it to the technical working group to put forth the literature and the procedures needed for that antigen to be rolled out in our laboratories. If that anti gen testing will be approved and the protocols be approved by the IATF, that will help ramp up and increase yung testing natin per day,” ayon kay Nograles.

Sa ngayon nasa 21,000 na COVID tests ang nagagawa ng bansa.

Una rito, sinabi ng Food and Drug Administration na hindi reliable ang antigen test gaya ng polymerase chain reaction tests.

 

 

TAGS: antigen test, covid pandemic, COVID-19, department of health, general community quarantine, Health, IATF, Inquirer News, Modified general community quarantine, News in the Philippines, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website, antigen test, covid pandemic, COVID-19, department of health, general community quarantine, Health, IATF, Inquirer News, Modified general community quarantine, News in the Philippines, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.